Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ESRRG | P62508 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022438 | 0.87 | KDM1A (0.33) | MEN1KMT2AMAPK1MGLLKDM2B | |
| SCHEMBL4027068 | 0.86 | GRIN1 (0.35) | MGLLKDM2BGRIN1GRIN2BKIF11 | |
| SCHEMBL4021304 | 0.83 | HRH3 (0.30) | — | |
| SCHEMBL4020633 | 0.82 | MEN1 (0.35) | MEN1KMT2AMAPK1MGLLKDM2B | |
| SCHEMBL4024566 | 0.81 | EED (0.33) | MEN1KMT2AKDM2BGRIN1GRIN2B | |
| SCHEMBL4751303 | 0.78 | KDM2B (0.33) | MEN1KMT2AMAPK1MGLLKDM2B | |
| SCHEMBL4019668 | 0.78 | HRH2 (0.34) | MEN1KMT2AMGLLKDM2BMC4R | |
| SCHEMBL4022053 | 0.78 | MGLL (0.36) | MEN1KMT2AMAPK1MGLLKDM2B | |
| SCHEMBL4028155 | 0.77 | KMT2A (0.34) | MEN1KMT2AMGLLKDM2BESRRG | |
| SCHEMBL4029269 | 0.77 | KDM2B (0.35) | MEN1KMT2AMGLLKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | MEN1 77/4885KMT2A 2820/4885MAPK1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.